Vitrolife AB (publ) becomes lead investor in AutoIVF
The Vitrolife Group today announces it has become a leading investor in AutoIVF. This strategic investment aligns with our corporate strategy of improving affordability and access to IVF to patients around the world.
AutoIVF, is an early-stage MedTech company with the aim to make IVF more accessible, affordable and efficient. Its technology, OvaReady™, is a groundbreaking automated system that simplifies and enhances egg retrieval and preparation, enabling high-quality fertility services in the current IVF process and also supports decentralising the egg retrieval process outside traditional IVF laboratory settings.
‘’This investment marks another step in our corporate strategy to build an end-to-end platform that connects products and services across the entire IVF workflow. By continuing to automate the IVF process we will enable safe, efficient and effective fertility care,” says Bronwyn Brophy O’Connor, CEO of the Vitrolife Group.
Ravi Kapur, CEO of AutoIVF, shares “With this new investment and partnership, we are excited to accelerate our path to market and explore collaborations that can expand access, scale innovation, and create lasting value across the reproductive health ecosystem”.
Financial impact is minimal, more details will be disclosed during the Q2 earnings release.
Gothenburg, May 8, 2025
VITROLIFE AB (publ)
Bronwyn Brophy O’Connor, CEO
Contact:
Amelie Wilson, Investor Relations, awilson@vitrolife.com
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.
Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452.Tel: +46 31 721 80 00. E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.